To succeed in China's fast-growing oncology market, multinational pharma companies need to look closely at their product mix and figure out whether getting listed on the country's reimbursed drug list will increase volume enough to offset price reductions, or whether it makes more sense to charge full retail prices to patients paying out-of-pocket and settle for lower volume
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.
Oral RNA splicing modulator has gone into a Phase II/III trial
Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.
